News & Updates

Show Multimedia Only
Novel tool spots potentially inappropriate prescribing in T2D

Novel tool spots potentially inappropriate prescribing in T2D

18 Jul 2024
Wearables on par with conventional tools for cardiac monitoring

Wearables on par with conventional tools for cardiac monitoring

18 Jul 2024
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease

Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease

18 Jul 2024
Upadacitinib proves long-term efficacy in RA

Upadacitinib proves long-term efficacy in RA

17 Jul 2024 byStephen Padilla

Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.

Upadacitinib proves long-term efficacy in RA

17 Jul 2024